Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

Practice-Changing and Reaffirming Data Set Up an Exciting Future in Melanoma

November 24th 2021

Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial with relatlimab and nivolumab, and the phase 3 KEYNOTE-716 trial with pembrolizumab, cemented 2021 as a banner year for the treatment of patients with melanoma, across various stages and subtypes.

FDA Grants RMAT Designation to CTX110 for Relapsed/Refractory CD19+ B-Cell Malignancies

November 23rd 2021

he FDA has granted a Regenerative Medicine Advanced Therapy designation to the allogeneic CAR T-cell therapy CTX110 for the treatment of patients with relapsed or refractory, CD19-positive B-cell malignancies.

Enasidenib/Azacitidine Combo Shows Early, Promising Activity in IDH2-Mutant AML

November 23rd 2021

The combination of enasidenib plus azacitidine was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia.

NBTXR3 Plus Radiotherapy Maintains Safety, Quality of Life in Soft Tissue Sarcoma

November 19th 2021

Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety results from the phase 2/3 Act.In.Sarc trial with NBTXR3 and radiotherapy in patients with soft tissue sarcoma.

mRNA COVID-19 Vaccines May Decrease Efficacy in Lymphoid Malignancies

November 19th 2021

Patients with lymphoid malignancies, especially those who have received recent anti-CD20 antibody therapy, have reduced humoral responses to the mRNA COVID-19 vaccines, and as such, should continue to take precautionary measures against COVID-19 infection irrespective of vaccination status.

Mortality Rate Associated With COVID-19 Breakthrough Cases Remains High in Hematologic Malignancies

November 18th 2021

Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available.

Addition of Bevacizumab to Pembrolizumab Improves Responses in Epithelial Ovarian Cancer

November 17th 2021

The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.

Loss of In-Person Patient Interaction is Key Factor in Pandemic-Related Burnout Among Oncologists

November 17th 2021

Although community oncologists and hematologists were concerned about loss of income during the COVID-19 pandemic, the loss of in-person patient interaction was cited as the key factor impacting their professional satisfaction.

Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas

November 15th 2021

The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.

Elimination of Perioperative Octreotide Does Not Increase Rate or Duration of Carcinoid Crisis in NETs

November 14th 2021

Prophylactic octreotide can be safely discontinued in patients with neuroendocrine tumors undergoing operation, as stopping its use has not been shown to increase the rate or duration of carcinoid crisis.

DuoBody®-CD3x5T4 Induces Efficient T-cell Activation, Tumor Cell Killing in HNSCC Cell Lines

November 12th 2021

The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.

Recent Developments Solidify Role of Immunotherapy in Advanced Urothelial Carcinoma

November 11th 2021

Matthew Galsky, MD, discusses the role of immunotherapy in urothelial cancer, as well as unmet needs and future research directions for this patient population.

First-in-class Anti-CD47 Fusion Protein DSP107 Under Investigation in AML and MDS

November 10th 2021

The FDA cleared an investigational new drug application for a phase 1b clinical trial examining DSP107, a first-in-class anti-CD47 fusion protein, in patients with acute myeloid leukemia and myelodysplastic syndrome.

Pembrolizumab/Lenvatinib Combo Under Investigation in Classic Kaposi Sarcoma

November 9th 2021

Alice Indini, MD, discusses the ongoing PULSAR trial examining pembrolizumab plus lenvatinib as a novel therapeutic option for patients with classic Kaposi sarcoma.

Addition of ADT to Radiation, and Prolonged ADT, Provide Clinical Benefit in Localized Prostate Cancer

November 8th 2021

The use of androgen deprivation therapy and prolongation of adjuvant ADT to at least 18 months in conjunction with definitive radiotherapy provides clinically meaningful benefit for patients with localized prostate cancer, irrespective of radiation dose.

Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC

November 8th 2021

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.

Varying Pathological Features Needed to Determine Prognosis in Myoepithelial Tumors

November 2nd 2021

There is significant clinical, pathological, and outcome heterogeneity in myoepithelial tumors and prognoses for these tumors cannot be determined by a single pathological feature, but rather, several patient and tumor characteristics.

Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma

November 1st 2021

The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.

RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic Alterations

October 27th 2021

The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.